Characteristics of New Drugs Approved in Korea in 2007~2018

Full metadata record

DC FieldValue
dc.contributor.authorSylvia Park
dc.contributor.authorSol-Leep Ha
dc.date.accessioned2020-06-26T04:24:34Z
dc.date.available2020-06-26T04:24:34Z
dc.date.issued2020-06-26
dc.identifier.urihttp://repository.kihasa.re.kr/handle/201002/35580
dc.description.abstractAs medicinal technologies continue to advance, the development of new drugs, especially those targeting serious conditions like cancer and rare diseases, has been on the global rise. These highpriced specialty drugs account for an increasing share of pharmaceutical expenditure. Also, facilitating the availability of new drugs has become a subject of growing attention, and new methods of ensuring prompt availability of new drugs, such as accelerated approval and risk-sharing arrangements (RSAs), have been used widely around the world. With the reliance on fast-track approvals growing, however, the evidence on which to base reimbursement decisions is becoming increasingly uncertain.
dc.formattext/plain
dc.formatapplication/octet-stream
dc.formatapplication/octet-stream
dc.format.extent8
dc.languageeng
dc.publisherKorea Institute for Health and Social Affairs
dc.rightsKOGL BY-NC-ND
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/
dc.rights.urihttp://www.kogl.or.kr/info/licenseType4.do
dc.titleCharacteristics of New Drugs Approved in Korea in 2007~2018
dc.typeArticle
dc.type.localArticle(Series)
dc.citation.titleResearch in Brief
dc.citation.number59
dc.citation.date2020-06-26
dc.citation.date2020-06-26
dc.citation.startPage1
dc.citation.endPage8
dc.identifier.bibliographicCitationResearch in Brief, no. 59, pp. 1 - 8
dc.date.dateaccepted2020-06-26T04:24:34Z
dc.date.datesubmitted2020-06-26T04:24:34Z

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

License License

Browse